Early Trial Data Show Promising Results for GM-CSF Blockade in CMML
Researchers are seeking to determine whether adding lenzilumab to standard-of-care treatment will improve outcomes in patients with CMML.
Diagnosis & Disease Information
Ianalumab, Ibrutinib Combination Promising in Chronic Lymphocytic Leukemia
Researchers sought to determine whether combination therapy with ianalumab and ibrutinib would have efficacy in patients with CLL.
Curative Potential Seen With Tafasitamab in R/R DLBCL
Researchers sought to determine whether tafasitamab would lead to durable responses in patients with R/R DLBCL.
Anti-LAG3, Anti-TIGIT Monoclonal Antibodies Active Against Relapsed/Refractory Multiple Myeloma
Researchers sought to determine the clinical activity of anti-LAG3 or anti-TIGIT monoclonal antibody therapy in patients with relapsed/refractory multiple myeloma.
REGN5459 Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
REGN5459 appears safe and can produce durable responses in patients with relapsed or refractory multiple myeloma, a phase 1/2 study suggests.
- Loading...
Loading...
Loading... 
Loading...